Next Phase Newsletter

A VC invests in US and Canada-based companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD). 
 
The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area. 
 
The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A global manufacturing company has a wide range of businesses including analytical instruments, medical devices, and industrial equipment. Recently, the firm has been focusing on healthcare, specifically in clinical diagnostics, and biomanufacturing. Last year, the firm established a corporate venture capital (CVC) department and is looking for strategic partnerships with companies with cutting-edge technology that align with their businesses. The fund will be managed for 10 years with a total investment of ¥5B JPY (~$50M USD). So far, the firm has invested in 3 companies and is looking to expand their investments in the States, though they are open to meeting with global companies. The fund is looking to invest in Pre-Seed to Early rounds but may invest as far as Series A. Typical check size can range from $1-10M USD but can exceed if there is a particularly strong interest in a technology. 
 
In terms of healthcare, the firm is looking to invest in clinical diagnostics, medical devices, and biomanufacturing. The firm is open to not only hardware but consumables as well. 
 
To attract investment from the firm, having a lead investor is desirable. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A Venture Capital firm is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor. 
 
The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data. 
 
The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring its investment to fund clinical trials and regulatory approval. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture fund based in the US invests in healthcare technology companies with a focus on healthcare infrastructure and enterprise solutions. The firm is currently investing out of its second, $50M fund, investing $1-2M (initially) in pre-seed to Series A companies. The firm will invest in companies that have a complete product and early customer traction. The firm will invest in companies based in the US or Canada, but when investing in Canada, the firm is focused on companies that are either targeting or entering the US market. 
 
The firm invests only in healthcare technology companies, with a focus on healthcare infrastructure solutions and enterprise software. This can include B2B healthcare solutions for providers, life sciences, and payers. Prior investments run the gamut from payment and credit tech, data structure and architecture, security, to next-gen patient acquisition tech. 
 
The firm generally will lead seed investments, and will sometimes co-lead or co-invest in Series A investments. Generally, the firm takes a board seat after investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm based in China and US manages about USD about 4 billion in committed capital with multiple USD and RMB funds. The firm typically invests in series A and B rounds; The firm can invest anywhere from a few million $ to tens of million $ over a 10 year horizon. At present, the firm is looking for new investment opportunities in US and greater China with excellent platform for long term growth. 
 
The firm seeks to invest in a broad array of technologies including therapeutics, MedTech, digital Health and etc. Within therapeutics, the firm is interested in innovative drugs and novel biotechnology based therapies. Within MedTech, the firm is interested in a great range of platforms that address large unmet medical need globally. The firm is opportunistic in terms of subsectors and stage of development. Historically, the firm invested in immuno-oncology drugs, CNS drugs, gene therapy and gene editing, digital health and AI-backed diagnostics, radiology imaging, clinical cell and molecular genetics testing, POC devices, diagnostics and genomics, and so on. 
 
The firm is looking for competent and experienced management teams. The firm typically seeks a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm acts as a drug discovery copilot and seed investor. The firm has a unique copiloting model where they can help founders stay incredibly lean while generating the preclinical data package necessary for a high-quality Series A. The firm invests in therapeutics companies at the Seed stage and what may sometimes look like a Series A round with typical check sizes ranging from $5-10M USD. The firm can be first or second money in and is geography-agnostic. 
 
The firm solely invests in therapeutics and is modality- and indication-agnostic. Companies can be single asset or platform focused. The firm can fund anything from a well-defined “idea on paper” to existing companies with significant proof of concept data. 
 
The firm does not have specific management team requirements. The firm acts as a lead investor and typically does not take a controlling position but requests a right to take a board seat if applicable. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm with offices in Canada is primarily interested in investing in companies in the digital health sector but will also consider medical and diagnostic devices that have a significant digital component to them. Esplanade is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD $0.5M-2.5M. The firm is currently operating out of its second fund in which it has made five investments after making thirteen investments out of its inaugural fund. Esplanade participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel. 
 
The firm is primarily interested in investing in companies in the digital health sector but will also consider medical and diagnostic devices that have a significant digital component to them. The firm is open to all modalities within digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in developing as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology. 
 
The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat or board observer role as determined by check size on a case-by-case basis. The firm will participate both as lead and co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.